EnrollingPreclinical Alzheimer's Disease Study
Phase 1 research study evaluating the safety and tolerability of an investigational vaccine in older adults who have no memory or thinking problems but show early biological signs of Alzheimer's disease.
- Age
- 65 to 80 years old
- Who
- Adults with normal memory and thinking, confirmed by screening tests
- Length
- About 17 months, including screening and follow-up visits























